Advertisement

Topics

Pfizer Announces Top-Line Results from the Oral Strategy Trial of Xeljanz Compared to Humira

09:57 EST 17 Feb 2017 | Speciality Pharma Journal

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab …

Original Article: Pfizer Announces Top-Line Results from the Oral Strategy Trial of Xeljanz Compared to Humira

NEXT ARTICLE

More From BioPortfolio on "Pfizer Announces Top-Line Results from the Oral Strategy Trial of Xeljanz Compared to Humira"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...